Fluvoxamine – an antidepressant close to Prozac – would be effective in reducing the risk of hospitalization in patients with Covid-19.
Will fluvoxamine be added to the long list of treatments that have raised hopes in vain in this pandemic? At a time when everyone has only one idea in mind, turn the page on Covid, a study just published in The Lancet Global Health puts a coin back in the machine by claiming that this drug – an antidepressant close to Prozac – would be effective in reducing the risk of hospitalization in patients with Covid-19. Medical revolution for some, very questionable results for others: this announcement is far from unanimous within the scientific community.
The study in question was carried out in 11 Brazilian hospitals, among 1,700 patients infected with the virus. The latter were chosen because they had at least one risk factor for developing a serious form (cardiovascular problem, hypertension, diabetes, lung disease, obesity, etc.). Half of them were given the antidepressant drug to take two